日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

多模式肿瘤非特异性ctDNA分析用于卵巢癌微小残留病灶检测和风险分层:MITO16a/MaNGO-OV2试验结果

Paracchini, L; Velle, A; Di Gennaro, P; Mannarino, L; Ancona, L; Lorusso, D; Cecere, S C; Colombo, N; Beltrame, L; Fagotti, A; Tasca, G; Piemontese, M; Arenare, L; Califano, D; Galdiero, F; Zadro, R; Chiodini, P; Perrone, F; Biagioli, E; D'Incalci, M; Romualdi, C; Pignata, S; Marchini, S

CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

CCDC6免疫染色联合Rad51 HRD检测可能扩大PARP抑制剂治疗在高级别浆液性卵巢癌患者中的适用范围。

Daniela Criscuolo,Francesco Merolla,Benedetta Pellegrino,Luca Russolillo,Ilaria De Benedictis,Daniela Califano,Rosaria Catalano,Carmela Baviello,Silvia Varricchio,Sabrina C Cecere,Camilla Nero,Eleonora Palluzzi,Dionyssios Katsaros,Ettore D Capoluongo,Giovanni L Scaglione,Sergio Marchini,Daniela Russo,Anna Spina,Laura Arenare,Francesco Morra,Maria Marotta,Marialuisa A Vecchione,Alexandra Ingallinella,Francesco Perrone,Sandro Pignata,Angela Celetti

Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients

HOBOE III期试验十年更新结果,比较曲普瑞林联合他莫昔芬或来曲唑,或唑来膦酸联合来曲唑治疗绝经前激素受体阳性早期乳腺癌患者

Gravina, A; Gargiulo, P; De Laurentiis, M; Arenare, L; De Placido, S; Orditura, M; Cinieri, S; Riccardi, F; Ribecco, A S; Putzu, C; Del Mastro, L; Rossi, E; Ciardiello, F; Di Rella, F; Nuzzo, F; Pacilio, C; Caputo, R; Cianniello, D; Forestieri, V; Giuliano, M; Arpino, G; Orlando, L; Mocerino, C; Schettino, C; Piccirillo, M C; Gallo, C; Perrone, F

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib

HR-SC 是一个学术界开发的机器学习框架,用于对 HRD 阳性卵巢癌患者进行分类并预测其对奥拉帕尼的敏感性。

Beltrame, L; Mannarino, L; Sergi, A; Velle, A; Treilleux, I; Pignata, S; Paracchini, L; Harter, P; Scambia, G; Perrone, F; González-Martin, A; Berger, R; Arenare, L; Hietanen, S; Califano, D; Derio, S; Van Gorp, T; Dalessandro, M L; Fujiwara, K; Provansal, M; Lorusso, D; Buderath, P; Masseroli, M; Ray-Coquard, I; Pujade-Lauraine, E; Romualdi, C; D'Incalci, M; Marchini, S

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

晚期子宫内膜癌同源重组修复状态:来自随机 II 期 MITOEND 3 试验的探索性生物标志物分析

Bartoletti, M; Passarelli, A; Fagotti, A; Andreetta, C; Tamberi, S; Lorusso, D; Pisano, C; Califano, D; Spina, A; De Angelis, C; Greco, F; De Cecio, R; Scaglione, G L; Russo, D; Ghizzoni, V; Cinieri, S; Sisoudiya, S D; Sokol, E S; Arenare, L; Schettino, C; Perrone, F; Farolfi, A; Pignata, S

Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial

肿瘤浸润白细胞作为贝伐珠单抗治疗卵巢癌患者的预后生物标志物:来自 IV 期 MITO16A/MaNGO OV-2 临床试验的结果

Pivetta, Eliana; Canzonieri, Vincenzo; Bagnoli, Marina; Chiodini, Paolo; Spina, Anna; Arenare, Laura; Lorusso, Domenica; Tasca, Giulia; Cecere, Sabrina C; Ferrero, Annamaria; Scognamiglio, Giosuè; Basso-Valentina, Francesca; Califano, Daniela; De Cecco, Loris; Di Lauro, Teresa; Nicoloso, Milena S; Arcieri, Martina; Russo, Daniela; Spessotto, Paola; Indraccolo, Stefano; Mezzanzanica, Delia; Perrone, Francesco; Pignata, Sandro; Baldassarre, Gustavo

Comparison of baseline patient characteristics in phase 1 and phase 2/3 clinical trials for anticancer treatments

抗癌治疗1期和2/3期临床试验中基线患者特征的比较

Iacovino, Maria Lucia; Talucci, Simone; Arenare, Laura; Caglio, Andrea; Canciello, Andrea; Salerno, Flavio; Facchini, Sergio; Gravina, Adriano; Schettino, Clorinda; Piccirillo, Maria Carmela; Olimpieri, Pier Paolo; Di Maio, Massimo; Perrone, Francesco

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial

结合基因组学和功能性方法揭示卵巢癌 HRD 评估的复杂性:MITO16-MaNGO-OV-2 试验的转化分析

B Pellegrino, E D Capoluongo, M Bagnoli, L Arenare, D Califano, G Scambia, S C Cecere, E M Silini, G L Scaglione, A Spina, G Tognon, N Campanini, C Pisano, D Russo, A Pettinato, P Scollo, R Iemmolo, L De Cecco, A Musolino, S Marchini, L Beltrame, L Paracchini, F Perrone, D Mezzanzanica, S Pignata6

Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study

程序性死亡配体1表达及其在贝伐珠单抗治疗的卵巢癌患者中的预后意义:来自IV期MITO16A/MaNGO OV-2转化研究的结果

Basso-Valentina, Francesca; Canzonieri, Vincenzo; De Cecio, Rossella; Arenare, Laura; Lorusso, Domenica; Cecere, Sabrina Chiara; Pivetta, Eliana; Russo, Daniela; Di Mauro, Annabella; Artioli, Grazia; Spina, Anna; De Angelis, Carmine; Califano, Daniela; Cinieri, Saverio; Scognamiglio, Giosuè; Salutari, Vanda; Chiodini, Paolo; Perrone, Francesco; Pignata, Sandro; Baldassarre, Gustavo

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).

外周单核细胞髓系衍生抑制细胞与接受卡铂+紫杉醇/avelumab治疗的单中心子宫内膜癌患者的分子亚型的关联(MITO-END3试验)

D'Alterio C, Rea G, Napolitano M, Coppola E, Spina A, Russo D, Azzaro R, Mignogna C, Scognamiglio G, Califano D, Arenare L, Schettino C, Pisano C, Cecere S C, Di Napoli M, Passarelli A, Perrone F, Pignata S, Scala S